✨ Free AI Report
Lyra Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Lyra Therapeutics, Inc.
Company Research

Lyra Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Lyra Therapeutics, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). High clinical risk due to operational suspension and strategic uncertainty despite positive efficacy data. Despite positive Phase 3 data, the company suspended development and ceased operations in January 2026, citing strategic concerns. With only $22.1M in cash (Sept 2025) and a micro-cap valuation around $3.5M, the company faces existential.

What is Lyra Therapeutics, Inc.'s industry? Lyra Therapeutics, Inc. (lyratherapeutics.com) operates in Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation). AskCyborg classifies Lyra Therapeutics, Inc. under Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation) in its company registry.

Lyra Therapeutics is a clinical-stage biotech company developing long-acting, anti-inflammatory nasal inserts for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million Americans. The c...

3/ 10Challenged

Cyborg Score thesis

High clinical risk due to operational suspension and strategic uncertainty despite positive efficacy...

Read the full analyst-debate transcript →
Industry Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation)
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Lyra Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Lyra Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Lyra Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Lyra Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Lyra Therapeutics, Inc. Overview

Pro stress-test →

Lyra Therapeutics is a clinical-stage biotech company developing long-acting, anti-inflammatory nasal inserts for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million Americans. The company's lead candidate LYR-210 is a bioabsorbable nasal mesh designed to deliver six months of continuous medication via a simple in-office procedure.

Strategic Profile

Pro stress-test →

Lyra demonstrated clinical success with positive Phase 3 ENLIGHTEN 2 data in June 2025, meeting primary endpoints. However, the company announced in January 2026 that its Board suspended further LYR-210 development and ceased operations while pursuing strategic alternatives, representing a significant strategic pivot amid capital constraints.

Competitive Landscape

Pro stress-test →

Direct competitors in sinonasal delivery include emerging biotech firms, though CRS treatment remains underserved with limited approved therapies. Broader competition includes conventional systemic and topical anti-inflammatory treatments, saline rinses, and surgical interventions. Lyra's unique drug-delivery mechanism differentiates it but execution risk is elevated.

Industry Context

Lyra Therapeutics, Inc. operates in Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation).

Key facts

Founded: 2005 · Headquarters: Watertown, MA · Employees: 28 · Revenue: $600K · Market cap: $3.5M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Lyra Therapeutics, Inc..

  • Phase 3 ENLIGHTEN 2 trial met primary endpoint with statistically significant symptom improvement, validating mechanism of action
  • Company suspended LYR-210 development in January 2026 and pivoting to explore strategic alternatives with advisors
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Board suspended LYR-210 development, ceased operations, and engaged advisors for strategic alternatives
  • November 2025Announced new confirmatory Phase 3 trial plan while reporting $22.1M cash position
  • +2 moreTrack every material event for Lyra Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Lyra Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Conventional CRS ManagementSaline rinses, oral corticosteroids, antibiotics, and endoscopic sinus surgery→Systemic Anti-inflammatory TherapiesOral corticosteroids and immunosuppressants for CRS management→

Compare Lyra Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Lyra Therapeutics, Inc. operates in Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation) research →
NEW · MCP server

Ask your AI assistant about Lyra Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Lyra Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Lyra Therapeutics, Inc. do this quarter?”
“Is Lyra Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Lyra Therapeutics, Inc. do?+
Lyra Therapeutics is a clinical-stage biotech company developing long-acting, anti-inflammatory nasal inserts for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million Americans. The c...
What is Lyra Therapeutics, Inc.'s Cyborg Score?+
Lyra Therapeutics, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Lyra Therapeutics, Inc.'s main competitors?+
Named competitors include Conventional CRS Management, Systemic Anti-inflammatory Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Lyra Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Lyra Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Lyra Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.